New drug aims to tame rare inflammatory disease
NCT ID NCT05263934
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether a new drug, depemokimab, works as well as the current treatment mepolizumab for adults with a rare disease called EGPA, which causes inflammation of blood vessels. The study involves 163 participants and aims to see if depemokimab can help patients achieve remission while reducing their steroid use. Results are expected after 52 weeks of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
depemokimab (compared to mepolizumab)
What this could lead to
If depemokimab works as well as mepolizumab, it could offer a new treatment option for EGPA, potentially with less frequent dosing.
What could go wrong
This is a non-inferiority trial, so depemokimab may not be better than the existing drug. Results are still pending, and individual responses may vary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Denver, Colorado, 80206, United States
-
GSK Investigational Site
Gainesville, Florida, 32610, United States
-
GSK Investigational Site
Rochester, Minnesota, 55905, United States
-
GSK Investigational Site
New York, New York, 10021, United States
-
GSK Investigational Site
Charlotte, North Carolina, 28211, United States
-
GSK Investigational Site
Pittsburgh, Pennsylvania, 15261, United States
-
GSK Investigational Site
La Plata, B1900, Argentina
-
GSK Investigational Site
San Miguel de Tucumán, T4000, Argentina
-
GSK Investigational Site
Graz, 8036, Austria
-
GSK Investigational Site
Santo André, 09060-870, Brazil
-
GSK Investigational Site
São Paulo, 4023900, Brazil
-
GSK Investigational Site
Toronto, Ontario, M5T 3A9, Canada
-
GSK Investigational Site
Toronto, Ontario, M5T 3L9, Canada
-
GSK Investigational Site
Beijing, 100005, China
-
GSK Investigational Site
Guangzhou, 510163, China
-
GSK Investigational Site
Hefei, 230001, China
-
GSK Investigational Site
Nanjing, 210006, China
-
GSK Investigational Site
Qingdao, 266071, China
-
GSK Investigational Site
Shanghai, 200032, China
-
GSK Investigational Site
Shenzhen, 518020, China
-
GSK Investigational Site
Wenzhou, 325000, China
-
GSK Investigational Site
La Roche-sur-Yon, 85925, France
-
GSK Investigational Site
Nantes, 44093, France
-
GSK Investigational Site
Paris, 75014, France
-
GSK Investigational Site
Freiburg im Breisgau, 79106, Germany
-
GSK Investigational Site
Minden, 32429, Germany
-
GSK Investigational Site
Ramat Gan, 52621, Israel
-
GSK Investigational Site
Bari, 70124, Italy
-
GSK Investigational Site
Brescia, 25123, Italy
-
GSK Investigational Site
Florence, 50134, Italy
-
GSK Investigational Site
Milan, 20132, Italy
-
GSK Investigational Site
Milan, 20162, Italy
-
GSK Investigational Site
Pavia, 27100, Italy
-
GSK Investigational Site
Pisa, 56126, Italy
-
GSK Investigational Site
Roma, 00128, Italy
-
GSK Investigational Site
Torrette AN, 60126, Italy
-
GSK Investigational Site
Treviso, 31100, Italy
-
GSK Investigational Site
Kanagawa, 247-8533, Japan
-
GSK Investigational Site
Kanagawa, 252-0392, Japan
-
GSK Investigational Site
Saitama, 350-8550, Japan
-
GSK Investigational Site
Tokyo, 162-8666, Japan
-
GSK Investigational Site
Tokyo, 181-8611, Japan
-
GSK Investigational Site
Groningen, 9713 GZ, Netherlands
-
GSK Investigational Site
Leiden, 2333 ZA, Netherlands
-
GSK Investigational Site
Gdansk, 80-952, Poland
-
GSK Investigational Site
Lodz, 90-153, Poland
-
GSK Investigational Site
Warsaw, 01-138, Poland
-
GSK Investigational Site
Lisbon, 1649-035, Portugal
-
GSK Investigational Site
Porto, 4099-001, Portugal
-
GSK Investigational Site
Gwangju, 61469, South Korea
-
GSK Investigational Site
Seoul, 05505, South Korea
-
GSK Investigational Site
Seoul, 06351, South Korea
-
GSK Investigational Site
Seoul, 06591, South Korea
-
GSK Investigational Site
Seoul, 3080, South Korea
-
GSK Investigational Site
Barcelona, 08035, Spain
-
GSK Investigational Site
Barcelona, 08036, Spain
-
GSK Investigational Site
Granada, 18014, Spain
-
GSK Investigational Site
Pamplona, 31008, Spain
-
GSK Investigational Site
Zaragoza, 50009, Spain
-
GSK Investigational Site
Malmö, SE-205 02, Sweden
-
GSK Investigational Site
Birmingham, B15 2GW, United Kingdom
-
GSK Investigational Site
Cambridge, CB2 2QQ, United Kingdom
-
GSK Investigational Site
London, SE1 7EH, United Kingdom